In May 2025, the first children with medulloblastoma received the experimental treatment in the MATCHPOINT study, representing an unprecedented breakthrough funded by MBI. While these initial patients begin therapy, new pediatric and young adult participants with recurrent or refractory medulloblastoma continue to be recruited for the clinical trial in the U.S.
FDA-approved in 2024, the study launched in March and is now progressing, monitoring twelve patients over two years, offering tangible hope for cases that previously lacked effective treatment options.
The innovative approach combines modified T-cell therapy with immune activators, effectively “teaching” the immune system to target and destroy tumors with precision. “A breakthrough inconceivable just three years ago“, emphasizes Fernando Goldsztein, MBI’s founder.
To learn more about the trial and enrollment, click here.
